Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

162.18
Delayed Data
As of Sep 04
 -2.07 / -1.26%
Today’s Change
137.34
Today|||52-Week Range
194.73
-0.95%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$9.9B

Company Description

Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products. The company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded on January 18, 2012 and is headquartered in Dublin, Ireland.

Contact Information

Jazz Pharmaceuticals Plc
Connaught House
Dublin Dublin 4
P:(531) 634-7800
Investor Relations:
(531) 634-7887

Employees

Shareholders

Mutual fund holders63.78%
Other institutional31.57%
Individual stakeholders18.35%

Top Executives

Bruce C. CozaddChairman & Chief Executive Officer
Russell J. CoxChief Operating Officer & Executive Vice President
Matthew P. YoungChief Financial Officer & Executive Vice President
Mark G. EllerSenior VP-Research & Clinical Development
Karen L. SmithChief Medical Officer & Global Head-Research